A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Latest Information Update: 24 Mar 2026
At a glance
- Drugs INCA 036978 (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Myeloproliferative disorders; Polycythaemia vera
- Focus Adverse reactions
- Sponsors Incyte Corporation
Most Recent Events
- 19 Mar 2026 Planned initiation date changed from 26 Feb 2026 to 29 Mar 2026.
- 19 Mar 2026 Status changed from not yet recruiting to recruiting.
- 06 Mar 2026 New trial record